SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ____________________ to ____________________
Commission File number
ALGOS PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-3142274
(State or other jurisdiction of incorporation (I.R.S. Employer Identification No.)
or organization)
1333 Campus Parkway, Neptune, New Jersey, 07753-6815
(Address of principal executive offices)
732-938-5959
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the registrant was required
to file such reports) and has been subject to such filing requirements for the
past 90 days. Yes X No
--- ---
The aggregate number of shares of the Registrant's common stock outstanding on
July 27, 1999 was 17,366,545.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
BALANCE SHEETS
(Unaudited)
December 31, June 30,
1998 1999
---- ----
ASSETS
Current assets:
Cash and cash equivalents $37,025,445 $ 30,045,049
Marketable securities 9,001,528 12,005,745
Interest receivable 417,042 260,062
Prepaid expenses and other current assets 683,866 148,218
----------- ------------
Total current assets 47,127,881 42,459,074
Marketable securities, noncurrent 4,052,824
Restricted cash 150,000 150,000
Property and equipment, net 1,098,819 1,187,901
----------- ------------
Total assets $52,429,524 $ 43,796,975
=========== ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 2,117,795 $ 3,702,155
Other current liabilities 794,044 569,393
----------- ------------
Total current liabilities 2,911,839 4,271,548
----------- ------------
Commitments
Stockholders' equity:
Common stock, $.01 par value, 50,000,000 shares authorized,
17,028,649 and 17,366,545 shares issued and outstanding, respectively 170,287 173,666
Additional paid-in-capital 81,626,800 81,773,110
Unearned compensation expense (611,108) (323,163)
Deficit accumulated during the development stage (31,668,294) (42,098,186)
----------- ------------
Total stockholders' equity 49,517,685 39,525,427
----------- ------------
Total liabilities and stockholders' equity $52,429,524 $43,796,975
=========== ============
The accompanying notes are an integral part of these financial statements.
1
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
STATEMENTS OF OPERATIONS
(Unaudited)
For the three months ended For the six months ended Cumulative
June 30, June 30, from inception
----------------------------- ----------------------------- to June 30,
1998 1999 1998 1999 1999
---- ---- ---- ---- ----
Revenues $ -- $ -- $ -- $ -- $ 3,311,000
------------ ------------ ------------ ------------ -------------
Operating expenses:
Research and development 3,783,018 3,050,801 7,003,478 5,567,790 34,229,920
Selling, general and administrative 1,114,847 2,476,240 1,856,379 5,938,289 17,864,816
------------ ------------ ------------ ------------ -------------
Total operating expenses 4,897,865 5,527,041 8,859,857 11,506,079 52,094,736
------------ ------------ ------------ ------------ -------------
Loss from operations (4,897,865) (5,527,041) (8,859,857) (11,506,079) (48,783,736)
Interest income 515,615 507,729 1,079,804 1,076,187 6,685,550
------------ ------------ ------------ ------------ -------------
Net loss $ (4,382,250) $ (5,019,312) $ (7,780,053) $(10,429,892) $(42,098,186)
============ ============ ============ ============ =============
Net loss per common share, basic
and diluted $ (0.27) $ (0.29) $ (0.49) $ (0.60)
============ ============ ============ ============
Weighted average common
shares outstanding, basic
and diluted 15,999,551 17,304,760 15,977,459 17,301,947
============ ============ ============ ============
The accompanying notes are an integral part of these financial statements.
2
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Cumulative
For the six months ended June from inception
30, to June 30,
1998 1999 1999
---- ---- ----
Cash flows from operating activities $ (6,079,205) $ (8,210,735) $(35,772,213)
Cash flows from investing activities:
Purchases of marketable securities (13,063,945) (9,842,358) (76,753,015)
Redemption of marketable securities 11,000,000 64,853,072
Purchases of property and equipment (918,000) (201,492) (1,605,087)
------------ ------------ ------------
Net cash used in investing activities (13,981,945) 956,150 (13,505,030)
------------ ------------ ------------
Cash flows from financing activities:
Proceeds from issuance of preferred stock 6,659,015
Proceeds from issuance of common stock 123,125 274,189 72,663,277
------------ ------------ ------------
Net cash provided by financing activities 123,125 274,189 79,322,292
------------ ------------ ------------
Net increase (decrease) in cash and cash equivalents (19,938,025) (6,980,396) 30,045,049
Cash and cash equivalents, beginning of period 20,246,152 37,025,445 --
------------ ------------ ------------
Cash and cash equivalents, end of period $ 308,127 $ 30,045,049 $ 30,045,049
============ ============ ============
The accompanying notes are an integral part of these financial statements.
3
ALGOS PHARMACEUTICAL CORPORATION
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
1. BASIS OF PRESENTATION
The financial statements presented herein have been prepared in accordance
with generally accepted accounting principles for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X and are
unaudited. In the opinion of management, the financial statements reflect all
adjustments (which consist of normal recurring accruals and adjustments)
necessary for a fair statement of the financial position and results of the
interim periods presented.
2. LOSS PER SHARE
Since the Company incurred net losses in all periods presented, outstanding
options and warrants to purchase an aggregate of 1,270,415 and 1,353,341 shares
of Common Stock at June 30, 1998 and 1999, respectively, were not included in
diluted per share calculations, as their effect would be antidilutive.
3. OTHER CURRENT LIABILITIES
Other Current Liabilities consist of the following:
December 31, June 30,
1998 1999
---- ----
Accrued compensation $ 318,800 $ 471,257
Accrued research expenses 475,244 98,136
--------- ---------
Total $ 794,044 $ 569,393
========= =========
4. SUBSEQUENT EVENT
On August 2, 1999, Algos received a "not approvable" letter from the U.S.
Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for
MorphiDex'r'. FDA approval of an NDA is required for Algos to sell MorphiDex'r'
in the United States. "Not Approvable" letters are issued by the FDA for various
reasons and outline deficiencies that must be corrected prior to NDA approval.
In its letter to Algos, the FDA raised issues specifically related to the
adequacy of clinical trials, Algos' preclinical animal toxicology models and a
high-dose pharmacokinetic study. If the FDA requires Algos to perform further
clinical work, the potential approval of MorphiDex'r' could be substantially
delayed.
4
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
General
Algos, a development stage company, is engaged primarily in the development
and commercialization of proprietary pharmaceutical products. Since its
formation in January 1992, Algos has devoted a substantial amount of its efforts
to licensing technology, recruiting key management and staff, developing
products, filing patents and other regulatory applications and raising capital.
Algos has incurred losses since its inception and expects to incur losses
in the future as its existing development programs continue. Algos' product
development expenses may increase as additional drugs are developed. On
August 2, 1999, Algos received a "not approvable" letter from the U.S. Food
and Drug Administration regarding a New Drug Application (NDA) filed in 1998
for its most developmentally advanced drug, MorphiDex'r'. The Company will
incur additional costs for MorphiDex'r' as a result of the "not approvable"
letter. In addition, Algos may delay certain expenses associated with
pre-commercialization activities related to MorphiDex'r' such as the
establishment of a sales force, the preparation of promotional plans and
materials, additions to and changes in financial and operating systems, and
other related administrative activities.
Results of Operations
Six months ended June 30, 1999 and 1998
Research and development:
In the six months ended June 30, 1999, research and development expenses
were $5.6 million, a decrease of approximately $1.4 million, or 20%, from 1998.
In 1999, expenses decreased due to the impact in 1998 of large-scale, advanced
clinical trials and toxicology studies of MorphiDex'r'. These effects were
partially offset by expenses related to Phase II clinical studies of
HydrocoDex'TM' and the costs of obtaining drug supplies and manufacturing of
full-scale demonstration batches of MorphiDex'r' in 1999.
Selling, general and administrative:
In the six months ended June 30, 1999, selling, general and administrative
expenses were $5.9 million, an increase of approximately $4.1 million from 1998.
The significant increase was primarily attributable to the possible future
commercialization of products including fees to sales and marketing consultants,
costs of educational materials and activities, and the addition of marketing
personnel, as well as the general expansion of the Company's business
activities. Algos expects certain of these expenses to decrease pending
discussions with the FDA regarding the MorphiDex'r' NDA.
Three months ended June 30, 1999 and 1998
Research and development:
In the three months ended June 30, 1999, research and development expenses
were $3.1 million, a decrease of approximately $700,000, or 19%, from 1998. In
1999, expenses decreased due to the impact in 1998 of large-scale, advanced
clinical trials and toxicology studies of MorphiDex'r' and the costs of
preparing the MorphiDex'r' NDA. These expense reductions were partially offset
by expenses related to Phase II clinical studies of HydrocoDex'TM' and the costs
of obtaining drug supplies and manufacturing of full-scale demonstration batches
of MorphiDex'r' in 1999.
5
Selling, general and administrative:
In the three months ended June 30, 1999, selling, general and
administrative expenses were $2.5 million, an increase of approximately $1.4
million from 1998. The significant increase was primarily attributable to the
possible future commercialization of products including fees to sales and
marketing consultants, costs of educational materials and activities, and the
addition of marketing personnel, as well as the general expansion of the
Company's business activities. Algos expects certain of these expenses to
decrease pending discussions with the FDA regarding the MorphiDex'r' NDA.
Liquidity and Capital Resources
Primarily as a result of its drug development efforts, the Company has
experienced net cash outflows from operations since its inception in 1992. In
the six months ended June 30, 1999, cash outflows from operations amounted to
approximately $8.2 million compared to $6.1 million in the first six months of
1998, primarily as a result of its increased expenses related to the possible
commercialization of MorphiDex'r'.
The Company expects to continue to incur product development expenses as
clinical trials of MorphiDex'r' and HydrocoDex'TM' continue and other drugs that
the Company currently has under development move into advanced clinical trials
and as additional drugs are developed and research and development staff
increases. On August 2, 1999, Algos received a "not approvable" letter from the
U.S. Food and Drug Administration regarding its NDA for MorphiDex'r'. As a
result of the "not approvable" letter, Algos will incur additional costs for
MorphiDex'r'. The Company currently expects that its cash and marketable
securities at June 30, 1999 will be sufficient to support a resubmission of the
NDA, if necessary, and fund its other planned development activities through the
year 2000. However, if additional trials are necessary or advisable, or if
additional products are developed, the Company may require additional funds. In
the event that internally generated funds are insufficient for such efforts, the
Company will need to raise additional funds either by incurring debt, issuing
additional equity or through collaborative or license arrangements to ensure
continuity of operations. There is no assurance that the Company would be able
to obtain such additional financing on terms acceptable to the Company.
The Company's future funding requirements will depend on a number of
factors, including: the results of its development efforts; the timing and costs
of obtaining required regulatory approvals; the amount of resources required for
the possible resubmission of the MorphiDex'r' NDA and potential continued
activities in preparation for the possible commercialization of MorphiDex'r';
the commercialization of competing products; the execution of licensing or other
collaborative research agreements on terms acceptable to the Company; and the
cost of prosecuting and defending patents.
Year 2000
A potential problem exists for all companies that rely on computers as the
year 2000 approaches. Algos' computer software applications and systems that use
only the last two digits of a year to refer to a year may not properly recognize
the year 2000. This phenomenon (the Year 2000 Issue) could cause a disruption of
operations, including, among other things, a temporary inability to engage in
normal business activities.
Algos is in the process of evaluating the impact of the Year 2000 Issue and
currently believes that the internal financial and operational systems of Algos,
as currently used, will function adequately with respect to the Year 2000 Issue.
This belief is based on Algos' correspondence with vendors and the fact that
Algos is not significantly reliant on its computer software applications and
systems during its developmental stage. However, if certain data management and
statistical applications do not function properly, the analysis and reporting of
study results could be delayed and the timing of subsequent development
activities and regulatory filings adversely affected. In the third quarter of
1999, Algos expects
6
to update certain of its purchased software with standard programs provided by
the software manufacturers and complete its testing of the updated programs.
Based on the results of this testing, Algos expects to develop any necessary
contingency plans in the fourth quarter of 1999.
Algos has limited information concerning the compliance status of its
third-party contractors. Algos' current third party contractors generally
perform clinical testing of Algos products and provide Algos with the results of
those tests, perform analytical laboratory testing, and manufacture drug
supplies. Algos is currently evaluating its correspondence with third-parties
regarding their readiness for the Year 2000 Issue. Various third parties have
advised Algos that their evaluation of their Year 2000 readiness is not
complete. Algos believes that many Year 2000 Issues for such third-party
contractors would not be material to Algos, since many activities could be
performed without the aid of a computer, or by alternative contractors. However,
disruption in the systems of drug suppliers and manufacturers could result in
interruptions in drug supplies and subsequently study delays or terminations. On
an ongoing basis, Algos will consider the need for purchasing inventories of
drug supplies.
As part of the possible future commercialization of products, Algos intends
to have third parties manufacture and distribute its products. Algos will place
significant dependence on the third parties' computer systems for purchasing,
production, customer order entry and invoicing and other related activities. A
disruption in these systems could result in lost revenue from inventory
shortages, improper execution of customer orders and/or delays in the resolution
and collection of outstanding invoices. In addition, Algos may make significant
additions to and changes in its existing computer software applications and
systems and/or the use of such systems . If Algos makes any such additions or
changes, it would affect Algos' exposure to the Year 2000 Issue since Algos
would become more reliant on its computer software applications and systems.
Therefore, Algos' assessment of its Year 2000 Issue and development of
contingency plans in these areas is ongoing.
At this time, Algos does not expect that the cost of its Year 2000 Issue
compliance program will be material to its business, financial condition, or
results of operations and does not currently anticipate any material disruption
in its operations. Algos has not incurred more than $10,000 of costs to date
related to the Year 2000 Issue.
Forward Looking Statements
This Report contains "forward-looking" statements, within the meaning of
Section 27A of Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, that are based on management's beliefs and
assumptions, current expectations, estimates, and projections. Statements that
are not historical facts, including statements which are preceded by, followed
by, or that include the words "believes;" "anticipates;" "plans;" "expects;" or
similar expressions and statements about the Company's development or
commercialization schedules and future use of funds are forward-looking
statements. Many of the factors that will determine the Company's future results
are beyond the ability of the Company to control or predict. These statements
are subject to risks and uncertainties and, therefore, actual results may differ
materially. The reader should not rely on any forward-looking statement. The
Company undertakes no obligations to update any forward-looking statements
whether as a result of new information, future events or otherwise. Important
factors that may affect future results include, but are not limited to:
uncertainty associated with pre-clinical studies and clinical trials and
regulatory approval; uncertainty of market acceptance of new products; impact of
competitive products and pricing; product development; changes in laws and
regulations; customer demand; possible future litigation; the availability of
future financing and reimbursement policies of government and private health
insurers and others. Readers should evaluate any statement in light of these
important factors. See "Risk Factors".
7
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
(a) The annual meeting of Stockholders of Algos Pharmaceutical Corporation was
held on June 21, 1999.
(b) The following Directors nominated by the Company were elected for
three-year terms:
John W. Lyle and Donald G. Drapkin
Roger H. Kimmel, Michael Hyatt, James R. Ledley and Dieter A. Sulser
continue their terms as Directors after the meeting.
(c) At the Annual Meeting, stockholders approved the following:
(i) Election of Directors:
Votes for: Votes Against or Withheld: Abstained:
John W. Lyle 15,722,954 2,132 0
Donald G. Drapkin 15,722,954 2,132 0
(ii) An amendment to the Company's Non-Employee Director Stock Option Plan to
increase the number of shares which may be granted under the plan by
200,000 and to increase the annual option grants to Non-Employee Directors
from 5,000 shares to 10,000 shares.
Votes for: Votes Against or Withheld: Abstained:
15,597,327 100,780 7,753
ITEM 5. OTHER INFORMATION
On August 2, 1999, Algos released the following press release addressing the
"not approvable" letter it received from the FDA with respect to the
MorphiDex'r' NDA:
"Algos Pharmaceutical Receives Not Approvable Letter From FDA for MorphiDex'r'
ALGOS PREPARED TO WORK CLOSELY WITH FDA TO RESOLVE ISSUES
NEPTUNE, NJ - August 2, 1999 - Algos Pharmaceutical Corporation (Nasdaq: ALGO)
today announced that it has received a "not approvable" letter from the U.S.
Food and Drug Administration (FDA) for MorphiDex'r', an NMDA enhanced opioid
analgesic. Algos submitted a New Drug Application (NDA) for MorphiDex'r' in
August 1998 for the treatment of moderate to severe cancer pain. MorphiDex'r' is
a patented combination of morphine and the NMDA-receptor antagonist
dextromethorphan.
"We are disappointed in the FDA's response to our NDA submission for
MorphiDex'r'," said John Lyle, President and Chief Executive Officer of Algos.
"We believe the submitted data support the safety and efficacy of MorphiDex'r'.
We are moving forward to address the issues raised by the FDA. In addition to
working with the FDA staff, the FDA process also allows a company to request a
review of an NDA submission by an FDA advisory committee."
Not approvable letters are issued by the FDA for various reasons and outline
deficiencies that must be corrected prior to approval. The applicant and the FDA
then discuss what further steps need to be taken before the NDA can be approved.
These steps usually involve the submission of additional data by the
8
company and the review of such data by the FDA. The FDA must review the
company's response to a deficiency letter within two or six months depending on
whether or not "substantial review work" is required. In its letter to Algos
dated August 2, 1999, the FDA raised issues specifically related to the adequacy
of clinical trials, Algos' preclinical animal toxicology models and a high-dose
pharmacokinetic study.
"We responded quickly to all FDA questions and requests for additional data
during the course of the NDA review period," Lyle added. "We will continue to
respond in this manner and are committed to working with the FDA to reach
resolution of the issues raised in the letter in a prompt manner."
"Algos will be discussing with the FDA whether it needs to perform additional
clinical work on MorphiDex'r'," Lyle said. "If further clinical work is
required, the potential approval of MorphiDex'r' could be substantially
delayed."
"With over $40 million in cash, we believe Algos has sufficient financial
resources to fully support a resubmission of the MorphiDex'r' NDA, including
completion of possible additional MorphiDex'r' clinical work," Lyle continued.
"In addition, we believe Algos has sufficient funds to continue the previously
planned development of the other products currently in the Company's pipeline."
Algos Pharmaceutical Corporation, based in Neptune, New Jersey, is a leader in
developing proprietary pain management products. The Company's products combine
existing analgesics and anesthetics with NMDA-receptor antagonist drugs. Algos'
products currently in development include opioid analgesics for
moderate-to-severe pain, non-opioid analgesics for mild-to-moderate pain,
long-lasting local anesthetics for post-operative pain, an intranasal anesthetic
for migraine and products for the treatment of opiate and nicotine addiction.
This news release contains "forward-looking" statements, within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, that are based on management's beliefs and
assumptions, current expectations, estimates and projections. Statements that
are not historical facts, including statements which are preceded by, followed
by, or that include the words "believes;" "anticipates;" "plans;" "expects;"
"estimates;" or similar expressions and statement about Algos are
forward-looking statements. Many of the factors that will determine Algos'
future results are beyond the ability of Algos to control or predict. These
statements are subject to risks and uncertainties and, therefore, actual results
may differ materially. The reader should not rely on any forward-looking
statement. Algos undertakes no obligation to update any forward-looking
statements whether as a result of new information, future events or otherwise.
The FDA review process is an uncertain one whose outcome cannot be guaranteed.
There is no guarantee the FDA will accept or approve any New Drug Application.
There is no guarantee Algos will be able to sufficiently address the issues
raised by the FDA in the MorphiDex'r' "not approvable" letter. Any Algos
response to the FDA on the MorphiDex'r' "not approvable" letter must be
reviewed by the FDA within two or six months depending on whether or not
"substantial review work" is required. There is no guarantee the FDA will grant
an approval of the MorphiDex'r' NDA as a result of the Algos response. There is
no guarantee the foregoing standards and timeline will not be changed.
Important factors that may affect Algos' future results include, but are
not limited to, uncertainty associated with pre-clinical studies and clinical
trials and regulatory approval, uncertainty of market acceptance of new
products, reimbursement policies of government and private health insurers,
impact of competitive products and pricing, product development, changes in laws
and regulations, customer demand, possible future litigation, and availability
of future financing."
9
Readers should evaluate any statements in light of these important factors. See
"Risk Factors" in Algos' Annual Reports on Form 10-K and Quarterly Reports on
Form 10-Q.
# # #
10
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
Exhibits:
Exhibit
No. Title
- --------- --------------------------------------------------------------------------------------
1.1 -- Purchase and Registration Rights Agreement, dated as of November 9, 1998(6)
3.1 -- Amended and Restated Certificate of Incorporation of Algos Pharmaceutical Corporation(1)
3.2 -- Amended and Restated By-laws of Algos Pharmaceutical Corporation(1)
4.1 -- Form of Stock Certificate of Common Stock(1)
4.2 -- Warrant to Purchase 250,000 Shares of Common Stock of Algos Pharmaceutical Corporation and Biotech Target
S.A., a Panamanian corporation, dated November 9, 1998(6)
5.1 -- Opinion of Latham & Watkins as to the validity of the Common Stock(1)
10.1.1 -- Employment Agreement with Respect to John W. Lyle(4)
10.1.3 -- Employment Agreement with Respect to Frank S. Caruso(1)
10.1.4 -- Employment Agreement with Respect to Joseph Sardella(5)
10.2.1 -- 1994 Stock Option Plan(1)
10.2.2 -- 1996 Stock Option Plan(1)
10.2.3 -- 1996 Non-Employee Director Stock Option Plan(2)
10.3.1 -- Algos Pharmaceutical Corporation Stockholders' Agreement(1)
10.4.1 -- License Agreement with The Medical College of Virginia(1)(A)
10.4.2 -- License Agreement with McNeil Consumer Products Company(1)(A)
10.4.3 -- Registration Rights Agreement with The Medical College of Virginia(1)
10.5 -- Lease Agreement with Commercial Realty & Resources Corp.(3)
21 -- Subsidiaries of the Registrant(1)
27 -- Financial Data Schedule
99 -- Risk Factors
(1) Incorporated by reference to the Registrant's registration statement on
Form S-1 declared effective on September 25, 1996.
(2) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1996.
(3) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 1997
(4) Incorporated by Reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1997.
(5) Incorporated by Reference to the Registrant's Quarterly Report on Form 10-Q
for the quarterly period ended June 30, 1998.
(6) Incorporated by Reference to the Registrant's registration statement on
Form S-3 dated March 10, 1999.
(A) Portions of this Exhibit have received confidential treatment pursuant to
Rule 406(b) under the Securities Act.
Reports on Form 8-K:
None.
11
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ALGOS PHARMACEUTICAL CORPORATION
Date August 16, 1999 /s/ John W. Lyle
-------------------- --------------------------------
John W. Lyle
President and Chief Executive Officer
Date August 16, 1999 /s/ Gary R. Anthony
-------------------- --------------------------------
Gary R. Anthony
Chief Financial Officer and Principal
Accounting Officer
12
STATEMENT OF DIFFERENCES
------------------------
The trademark symbol shall be expressed as ........................... 'TM'
The registered trademark symbol shall be expressed as ................ 'r'